Friday, February 10, 2023
DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.
Joe Gomes, Managing Director – Generalist Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
A Stronger DLH. The addition of GRSi is a transformative event, in our opinion, creating a more differentiated and powerful Company, with a combined nearly $1 billion of backlog and a new business pipeline that provides significant future growth opportunities. With favorable end markets, DLH is in the right place, at the right time, with the right solutions, in our view.
Strong Growth in Key Programs. DLH saw excellent growth in its key VA and HHS programs. VA pharmacy revenue rose 23% y-o-y to $19.2 million, VA logistics services revenue jumped 15% to $14.5 million, and HHS Head Start revenue increased 34% to $9.1 million, as services offered under this program returned to a more normal pre-COVID level.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.